|Healthcare Review: Obagi Medical Products, Anacor Pharmaceuticals, Progenics Pharmaceuticals, Albany Molecular, Intuitive Surgical|
|By Staff and Wire Reports|
|Friday, 15 March 2013 14:53|
U.S. stocks slipped on Friday, weighed by a decline in JPMorgan Chase shares after the bank was hit by a one-two punch of bad news and as investors paused just below the S&P 500's record high. Friday's dip also meant the Dow was on track to snap its 10-day winning streak during which it racked up a series of all-time highs. Equities have rallied since the start of the year on signs of improvement in the economy and supported by the Federal Reserve's efforts to bolster the recovery.
Following are notable movers at mid day on Friday:-
Obagi Medical Products, Inc. (NASDAQ:OMPI) Shares gained 7.39% to $.14.97. The company, on March 14, reported financial results for the fourth quarter and full-year ended December 31, 2012. Net sales for the fourth quarter of 2012 were $30.3 million, compared with the prior year quarter’s sales of $30.6 million. Net income for the fourth quarter of 2012 was $7.3 million, or $0.41 per diluted share. Adjusted non-GAAP net income for the fourth quarter of 2012 was $2.6 million, or $0.15 per diluted share.
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) Shares raised 4.59% to $3.87. The company, on March 14, announced its earnings results. Fourth-quarter revenues were $3.3 million, compared with $2.6 million in the year-ago quarter. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares surged 31.07% to $4.43. The company todayannounced its earnings results on Friday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.30. The company posted revenue of $8.87 million for the quarter, compared to the consensus estimate of $1.16 million.
Albany Molecular Research, Inc. (NASDAQ:AMRI) Shares declined 8.48%to $9.68. Zacks upgraded shares of AMRI from a neutral rating to an outperform rating in a research report released last week. Zacks currently has $10.30 price target on the stock.
Additionally, the company, on Feb. 25, announced that it has promoted Takeshi Yura, Ph.D., to Vice President of Discovery and Development Services, Asia. Dr. Yura will report directly to Thomas E. D'Ambra, Ph.D., Chairman, President and CEO.
Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares decreased 5.68% to $462.45 as a doctors’ group questioned the value of its da Vinci devices. The company has been on the defensive of late over a rise in reports of troubles with its machines, but officials said day before yesterday those are due mostly to a revised reporting practice
Additionally, the company will hold its quarterly conference call to discuss First Quarter 2013 results, Thursday, April 18, at 4:30 p.m. Eastern Time.